Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.

Abstract: Connectors and methods for contactless transfer of fluid between containers are disclosed. According to an aspect, a connector includes a body that defines a first end, a second end, and a passageway that extends between the first end and the second end, wherein the first end and second end are configured to attach to a first container and a second container, respectively. The passageway provides a pathway between the first and second containers when the first and second containers are attached to the first and second ends, respectively. Further, the connector includes an opener configured to engage and open the first container for release of a fluid from within the first container through the passageway and into the second container when the first and second containers are attached to the first and second ends, respectively.

Abstract: A profile or article formed from a moisture- and/or thermo-curable elastomeric polymer composition including: (A) at least one ethylene-olefinic monomer-silane polymer; wherein the polymer has an olefinic monomer content of from 5 weight percent to 50 weight percent and a silane content of from 0.1 weight percent to 2.5 weight percent; and wherein the polymer has a melt index of from 0.1 gram/10 minutes to 10.0 grams/10; and (B) at least one silanol condensation catalyst; a shaped article made from the above elastomeric polymer composition; and a method of making a shaped article using the above elastomeric polymer composition.

Abstract: A computer-implemented method for modifying one or more contents of an electronic learning system for a user impaired by a colour vision deficiency. The method includes: generating a vision profile for the user, the vision profile indicating at least a type of the colour vision deficiency, identifying, from the one or more contents, a content to be modified, the content including at least two portions formed of a first colour and a second colour, respectively, the first colour being different from the second colour but the first colour being at least partially indistinguishable from the second colour by the user due to the colour vision deficiency, identifying a content transformation to be applied to the content based on the vision profile, the content transformation including one or more adjustments of the content to accommodate the colour vision deficiency impairing the user; and applying the content transformation to the content.

Abstract: Systems and methods may use models to generate predictions of specific access rights for users. Further, systems and methods may generate the predictions in an environment in which the availability of the specific access rights change frequently. The access rights, predicted using embodiments described herein, may be both available and associated with user affinities. An interface associated with the primary load management system may be configured to display the predicted access rights for a user operating a user device.

Abstract: Disclosed herein are various methods and apparatus for performing charge detection mass spectrometry (CDMS). In particular, techniques are disclosed for monitoring a detector signal from a CDMS device to determine how many ions are present in the ion trap (10) of the CDMS device. For example, if no ions are present the measurement can then be terminated early. Similarly, if more than one ion is present, the measurement can be terminated early, or ions can be removed from the trap (10) until only a single ion remains. Techniques are also provided for increasing the probability of there being a single ion in the trap (10). A technique for attenuating an ion beam is also provided.

Abstract: Flange for a vacuum apparatus comprises a housing to be connected to the vacuum apparatus defining an opening wherein the opening has rectangular narrow shape. The flange further comprises a metal seal arranged around the opening to create a vacuum tight seal.

Abstract: A medical device inspection scope may include a cylindrical outer layer having a diameter of less than 2 millimeters or even less than 1 millimeter, a cylindrical inner layer disposed concentrically within the outer layer, a circumferential space between the outer layer and the inner layer, and an inner lumen formed by the inner layer. The scope also includes multiple light transmitting fibers disposed in the circumferential space and a camera module disposed in the inner lumen. The light fibers may be designed to transmit illumination light and ultraviolet light. The scope may also optionally include a stiffening member.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: A bonded multilayer article including: (a) at least one first layer of a silicone-containing rubber substrate material bonded to (b) at least one second layer of a substrate material bondable to the first layer; wherein at least a portion of the surface of the first layer is activated for adhesion to increase the bond strength of the first layer to a second layer such that the bond strength of the first layer bonded to the second layer is increased; and a process for producing the above bonded multilayer article.

Abstract: Provided herein are compositions, systems, and methods for causing weight loss and treating and/or preventing a disease or condition, such as obesity, diabetes, and cancer, with an agent or procedure that inhibits the TMA/FMO3/TMAO pathway in a subject.

Abstract: Disclosed herein are various methods and apparatus for performing charge detection mass spectrometry (CDMS). In particular, techniques are disclosed for monitoring a detector signal from a CDMS device to determine how many ions are present in the ion trap (10) of the CDMS device. For example, if no ions are present the measurement can then be terminated early. Similarly, if more than one ion is present, the measurement can be terminated early, or ions can be removed from the trap (10) until only a single ion remains. Techniques are also provided for increasing the probability of there being a single ion in the trap (10). A technique for attenuating an ion beam is also provided.

Abstract: Examples can include a system for video chat cycles within a social media application. An organizer platform can be used to design a schedule for the video chat cycles. This can include scheduled organizer content before, after, and between video chats. The organizer content can include graphics, video, and even live streams by the organizer.

Abstract: A rodent-proof barrier material comprising a settable carrier medium and a plurality of filaments dispersed within the settable carrier medium. Each filament of the plurality of filaments comprises a central curved portion and first and second end portions.

Abstract: Disclosed herein are various methods and apparatus for performing charge detection mass spectrometry (CDMS). In particular, techniques are disclosed for monitoring a detector signal from a CDMS device to determine how many ions are present in the ion trap (10) of the CDMS device. For example, if no ions are present the measurement can then be terminated early. Similarly, if more than one ion is present, the measurement can be terminated early, or ions can be removed from the trap (10) until only a single ion remains. Techniques are also provided for increasing the probability of there being a single ion in the trap (10). A technique for attenuating an ion beam is also provided.

Abstract: An expansion joint for providing a rodent-proof barrier. The expansion joint comprises an elongate core formed of a resiliently deformable material, and a flexible sheath of a barrier material covering at least a part of the elongate portion of the elongate core. The elongate portion of the elongate core is compressible in a direction perpendicular to a line between the first and second ends of the elongate core, the elongate core being arranged to be compressed and inserted into a gap between first and second building structures, and to expand after insertion into the gap so that the expansion joint is held in place within the gap by friction between the surface of the flexible sheath and the surfaces of the first and second building structures.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-634 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.